关注非T淋巴细胞在移植免疫中的作用

吴成林; 孙启全; LiXianChang

doi:10.3969/j.issn.1674-7445.2014.04.001

关注非T淋巴细胞在移植免疫中的作用

doi: 10.3969/j.issn.1674-7445.2014.04.001

1.
美国德克萨斯医疗中心休斯敦卫理公会医院免疫生物学研究中心（吴成林、Xian Chang Li）
2.
中山大学附属第三医院肾移植科（孙启全）

基金项目:

国家自然科学基金面上项目 81270834

详细信息

通讯作者:
Xian Chang Li (美国),医学和科学博士,教授。Xian Chang Li教授是国际移植免疫领域最著名的学者之一,目前担任美国德克萨斯医疗中心休斯敦卫理公会医院免疫生物学研究中心主任,康奈尔大学全职教授,曾在波士顿哈佛医学院工作,负责哈佛大学附属Brigham Hospital移植研究所。他是多个美国国立卫生研究院赞助的关于免疫耐受和排斥研究负责人,拥有3项移植免疫的专利,在《Nature Medicine》、《Nature Immunology》、《American Journal of Transplantation》等杂志发表文章110篇。兼任《器官移植》副总编辑,《Journal of Immnology》、《Transplantation》、《Current Opinion in Organ Transplantation》等多个杂志编委。两次获得美国移植学会杰出成就奖,担任中山大学器官移植研究所名誉所长,中山大学、中国科技大学客座教授。,Email:xcli@tmhs.org

中图分类号: R617;R392.4
计量
- 文章访问数: 98
- HTML全文浏览量: 26
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-25
- 网络出版日期: 2021-01-19
- 刊出日期: 2014-07-15

摘要

- 天然免疫 /
- 器官移植 /
- 免疫耐受 /
- 慢性排斥反应 /
- 自然杀伤细胞 /
- 单核巨噬细胞

HTML全文

参考文献(77)

[1]	Alegre ML, Florquin S, Goldman M. Cellular mechanisms underlying acute graft rejection: time for reassessment[J]. Curr Opin Immunol,2007,19(5):563-568. doi: 10.1016/j.coi.2007.07.019
[2]	Li XC. The significance of non-T-cell pathways in graft rejection: implications for transplant tolerance[J]. Transplantation,2010,90(10):1043-1047. doi: 10.1097/TP.0b013e3181efcfe9
[3]	Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction[J]. Curr Opin Organ Transplant,2008,13(4):339-343. doi: 10.1097/MOT.0b013e3283061115
[4]	Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells[J]. Nature,2009,457(7229):557-561. doi: 10.1038/nature07665
[5]	Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells[J]. Nat Immunol,2008,9(5):503-510. doi: 10.1038/ni1582
[6]	van der Touw W, Bromberg JS. Natural killer cells and the immune response in solid organ transplantation[J]. Am J Transplant,2010,10(6):1354-1358. doi: 10.1111/ajt.2010.10.issue-6
[7]	Benichou G, Yamada Y, Aoyama A, et al. Natural killer cells in rejection and tolerance of solid organ allografts[J]. Curr Opin Organ Transplant,2011,16(1):47-53. doi: 10.1097/MOT.0b013e32834254cf
[8]	Lin Y, Vandeputte M, Waer M. Natural killer cell-and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses[J]. J Immunol,1997,158(12):5658-5667. http://cn.bing.com/academic/profile?id=1536891815&encoded=0&v=paper_preview&mkt=zh-cn
[9]	Maier S, Tertilt C, Chambron N, et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28^-/- mice[J]. Nat Med,2001,7(5):557-562. doi: 10.1038/87880
[10]	Kroemer A, Xiao X, Degauque N, et al. The innate NK cells, allograft rejection, and a key role for IL-15[J]. J Immunol,2008,180(12):7818-7826. doi: 10.4049/jimmunol.180.12.7818
[11]	Cooper MA, Elliott JM, Keyel PA, et al. Cytokine-induced memory-like natural killer cells[J]. Proc Natl Acad Sci U S A,2009,106(6):1915-1919. doi: 10.1073/pnas.0813192106
[12]	Jungraithmayr W, Codarri L, Bouchaud G, et al. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells[J]. Am J Respir Crit Care Med,2013,187(12):1349-1359. doi: 10.1164/rccm.201209-1749OC
[13]	Yu G, Xu X, Vu MD, et al. NK cells promote transplant tolerance by killing donor antigen-presenting cells[J]. J Exp Med,2006,203(8):1851-1858. doi: 10.1084/jem.20060603
[14]	Laffont S, Seillet C, Ortaldo J, et al. Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells[J]. Blood,2008,112(3):661-671. doi: 10.1182/blood-2007-10-120089
[15]	Garrod KR, Liu FC, Forrest LE, et al. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity[J]. J Immunol, 2010,184(5):2329-2236. doi: 10.4049/jimmunol.0902748
[16]	van der Touw W, Burrell B, Lal G, et al. NK cells are required for costimulatory blockade induced tolerance to vascularized allografts[J]. Transplantation,2012,94(6):575-584. doi: 10.1097/TP.0b013e318264d3c4
[17]	Pratschke J, Stauch D, Kotsch K. Role of NK and NKT cells in solid organ transplantation[J]. Transpl Int,2009,22(9):859-868. doi: 10.1111/tri.2009.22.issue-9
[18]	Roy S, Barnes PF, Garg A, et al. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen[J]. J Immunol,2008,180(3):1729-1736. doi: 10.4049/jimmunol.180.3.1729
[19]	Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity[J]. Nat Rev Immunol,2011,11(11):750-761. doi: 10.1038/nri3088
[20]	Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease[J]. Nature,2013,496(7446):445-455. doi: 10.1038/nature12034
[21]	Tugal D, Liao X, Jain MK. Transcriptional control of macrophage polarization[J]. Arterioscler Thromb Vasc Biol,2013,33(6):1135-1144. doi: 10.1161/ATVBAHA.113.301453
[22]	Guo C, Buranych A, Sarkar D, et al. The role of tumor-associated macrophages in tumor vascularization[J]. Vasc Cell,2013,5(1):20. doi: 10.1186/2045-824X-5-20
[23]	Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic disorders: functions and regulation[J]. Curr Opin Lipidol,2011,22(5):365-372. doi: 10.1097/MOL.0b013e32834a77b4
[24]	Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections[J]. J Immunol,2008,181(6):3733-3739. doi: 10.4049/jimmunol.181.6.3733
[25]	Murai M, Hasegawa Volk M, Lee HM. Macrophage cytophilic antibodies in beagle renal allograft[J]. Surg Forum,1975,26:346-348. http://cn.bing.com/academic/profile?id=2463434941&encoded=0&v=paper_preview&mkt=zh-cn
[26]	Cruse JM, Whitten HD, Lewis GK, et al. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro[J]. Transplant Proc,1973,5(1):961-967. http://cn.bing.com/academic/profile?id=1557287323&encoded=0&v=paper_preview&mkt=zh-cn
[27]	Debray-Sachs M, Dy M, Hamburger J. Role of macrophage activation in allograft immunity: in vivo studies[J]. Ann Immunol,1979,130C(5):721-733. http://cn.bing.com/academic/profile?id=1497538682&encoded=0&v=paper_preview&mkt=zh-cn
[28]	Sund S, Reisaeter AV, Scott H, et al. Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies[J]. Clin Nephrol,2004,62(2):121-130. http://cn.bing.com/academic/profile?id=2318950580&encoded=0&v=paper_preview&mkt=zh-cn
[29]	Rowshani AT, Vereyken EJ. The role of macrophage lineage cells in kidney graft rejection and survival[J]. Transplantation,2012,94(4):309-318. doi: 10.1097/TP.0b013e318250c10f
[30]	Mannon RB. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?[J].Curr Opin Organ Transplant,2012,17(1):20-25. doi: 10.1097/MOT.0b013e32834ee5b6
[31]	Azzawi M, Hasleton PS, Hutchinson IV. TNF-alpha in acute cardiac transplant rejection[J]. Cytokines Cell Mol Ther,1999,5(1):41-49. http://cn.bing.com/academic/profile?id=2403586231&encoded=0&v=paper_preview&mkt=zh-cn
[32]	Wyburn K, Wu H, Yin J, et al. Macrophage-derived interleukin-18 in experimental renal allograft rejection[J]. Nephrol Dial Transplant,2005,20(4):699-706. doi: 10.1093/ndt/gfh712
[33]	Fahim T, B hmig GA, Exner M, et al. The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries[J]. Am J Transplant,2007,7(2):385-393. doi: 10.1111/ajt.2007.7.issue-2
[34]	Riquelme P, Tomiuk S, Kammler A, et al. IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients[J]. Mol Ther,2013,21(2):409-422. doi: 10.1038/mt.2012.168
[35]	Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1⁺ and IL-10-producing splenic macrophages and maintained by T regulatory cells[J]. J Immunol,2011,187(5):2405-2417. doi: 10.4049/jimmunol.1004175
[36]	Broichhausen C, Riquelme P, Geissler EK, et al. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation[J]. Curr Opin Organ Transplant,2012,17(4):332-342. http://cn.bing.com/academic/profile?id=2076216139&encoded=0&v=paper_preview&mkt=zh-cn
[37]	Magil AB. Monocytes/macrophages in renal allograft rejection[J]. Transplant Rev, 2009,23(4):199-208. doi: 10.1016/j.trre.2009.06.005
[38]	Kitchens WH, Chase CM, Uehara S, et al. Macrophage depletion suppresses cardiac allograft vasculopathy in mice[J]. Am J Transplant,2007,7(12):2675-2682. doi: 10.1111/ajt.2007.7.issue-12
[39]	Leibovich SJ, Polverini PJ, Fong TW, et al. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism[J]. Proc Natl Acad Sci U S A,1994,91(10):4190-4194. doi: 10.1073/pnas.91.10.4190
[40]	Grandaliano G, Gesualdo L, Ranieri E, et al. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection[J]. Transplantation,1997,63(3):414-420. doi: 10.1097/00007890-199702150-00015
[41]	Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha[J]. Nature,1987,329(6140):630-632. doi: 10.1038/329630a0
[42]	Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection[J]. J Am Soc Nephrol,2006,17(4):932-942. doi: 10.1681/ASN.2005121250
[43]	Li X, Chen Y, Tian L, et al. Increased iNOS-expressing macrophage in long-term surviving rat small-bowel grafts[J]. Am J Surg,2007,194(2):248-254. doi: 10.1016/j.amjsurg.2006.09.032
[44]	Dehmel S, Wang S, Schmidt C, et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome[J]. Eur J Immunol,2010,40(1):267-278. http://cn.bing.com/academic/profile?id=1981754960&encoded=0&v=paper_preview&mkt=zh-cn
[45]	Wang C, Tay SS, Tran GT, et al. Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance[J]. Transpl Immunol,2010,22(3/4):172-178.
[46]	Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance[J]. Science,2005,307(5707):254-258. doi: 10.1126/science.1102901
[47]	Steinman RM, Banchereau J. Taking dendritic cells into medicine[J]. Nature,2007,449(7161):419-426. doi: 10.1038/nature06175
[48]	Brenk M, Scheler M, Koch S, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4⁺ CD25⁺ Foxp3⁺ T regulatory cells[J]. J Immunol,2009,183(1):145-154. doi: 10.4049/jimmunol.0803277
[49]	Lucas M, Schachterle W, Oberle K, et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15[J]. Immunity,2007,26(4):503-517. doi: 10.1016/j.immuni.2007.03.006
[50]	Shortman K, Liu YJ. Mouse and human dendritic cell subtypes[J]. Nat Rev Immunol,2002,2(3):151-161. doi: 10.1038/nri746
[51]	Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance[J]. Nat Rev Immunol,2007,7(8):610-621. doi: 10.1038/nri2132
[52]	Thomson AW. Tolerogenic dendritic cells: all present and correct?[J]. Am J Transplant,2010,10(2):214-219. doi: 10.1111/ajt.2010.10.issue-2
[53]	Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance[J]. Transplantation,2008,85(3):369-377. doi: 10.1097/TP.0b013e3181612ded
[54]	Lin KL, Fulton LM, Berginski M, et al. Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD[J]. Blood,2014,123(10):1604-1614. doi: 10.1182/blood-2013-09-526020
[55]	Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts[J]. Nat Immunol,2006,7(6):652-662. doi: 10.1038/ni1333
[56]	Rogers NM, Isenberg JS, Thomson AW. Plasmacytoid dendritic cells: no longer an enigma and now key to transplant tolerance?[J]. Am J Transplant,2013,13(5):1125-1133. doi: 10.1111/ajt.12229
[57]	Zhong X, Gao W, Degauque N, et al. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells[J]. Eur J Immunol,2007,37(9):2400-2404. doi: 10.1002/(ISSN)1521-4141
[58]	Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: a tutorial on B cell survival[J]. Annu Rev Immunol,2003,21:231-264. doi: 10.1146/annurev.immunol.21.120601.141152
[59]	Kirk AD, Turgeon NA, Iwakoshi NN. B cells and transplantation tolerance[J]. Nat Rev Nephrol,2010,6(10):584-593. doi: 10.1038/nrneph.2010.111
[60]	Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance[J]. Transplant Rev,2010,24(2):67-78. doi: 10.1016/j.trre.2010.01.004
[61]	Terasaki PI, Cai J. Humoral theory of transplantation: further evidence[J]. Curr Opin Immunol,2005,17(5):541-545. doi: 10.1016/j.coi.2005.07.018
[62]	Zarkhin V, Sarwal MM. The coin toss of B cells in rejection and tolerance: danger versus defense[J]. Semin Immunol,2012,24(2):86-91. doi: 10.1016/j.smim.2011.09.003
[63]	Kwun J, Knechtle SJ. Overcoming chronic rejection:can it B?[J]. Transplantation,2009,88(8):955-961. doi: 10.1097/TP.0b013e3181b96646
[64]	Halloran PF. Immunosuppressive drugs for kidney transplantation[J]. N Engl J Med,2004,351(26):2715-2729. doi: 10.1056/NEJMra033540
[65]	Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports[J]. Transplant Proc,2013,45(3):1022-1025. doi: 10.1016/j.transproceed.2013.02.062
[66]	Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection[J]. Am J Transplant,2009,9(1):231-235. http://cn.bing.com/academic/profile?id=1512745446&encoded=0&v=paper_preview&mkt=zh-cn
[67]	Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production[J]. Am J Transplant,2009,9(1):201-209. http://cn.bing.com/academic/profile?id=1506252195&encoded=0&v=paper_preview&mkt=zh-cn
[68]	Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection[J]. Transplantation,2008,86(12):1754-1761. doi: 10.1097/TP.0b013e318190af83
[69]	Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies[J]. Am J Transplant,2010,10(3):681-686. doi: 10.1111/ajt.2010.10.issue-3
[70]	Burns AM, Ma L, Li Y, et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance[J]. J Immunol,2009,182(3):1314-1324. doi: 10.4049/jimmunol.182.3.1314
[71]	Porcheray F, Wong W, Saidman SL, et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans[J]. Am J Transplant,2009,9(9):2126-2135. doi: 10.1111/ajt.2009.9.issue-9
[72]	Deng S, Moore DJ, Huang X, et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes[J]. J Immunol,2007,178(10):6028-6032. doi: 10.4049/jimmunol.178.10.6028
[73]	Le Texier L, Thebault P, Lavault A, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile[J]. Am J Transplant,2011,11(3):429-438. doi: 10.1111/j.1600-6143.2010.03336.x
[74]	Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation[J]. Immunol Rev,2008,224:201-214. doi: 10.1111/imr.2008.224.issue-1
[75]	[CM(72.5mm]Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells[J]. Blood,2011,117(2):530-541.
[76]	Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients[J]. Immunity,2010,32(1):129-140. doi: 10.1016/j.immuni.2009.11.009
[77]	Redfield RR 3rd, Rodriguez E, Parsons R, et al. Essential role for B cells in transplantation tolerance[J]. Curr Opin Immunol,2011,23(5):685-691. doi: 10.1016/j.coi.2011.07.011